LO-CD2a antibody and uses thereof for inhibiting T cell activati

Details LO-CD2a antibody and uses thereof for inhibiting T cell activati LO-CD2a antibody and uses thereof for inhibiting T cell activati

1995-06-07

1998-03-24

Feisee, Lila

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

4241331, 4241431, 4241441, 4241531, 4241731, 5303873, 53038822, 5303887, 53038873, 53038875, 435 7021, 4351722, 435332, 435334, 435343, 4353432, A61K 39395, C07K 1628, C12N 512

Patent

active

057309795

ABSTRACT:
The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.

REFERENCES:
patent: 5283058 (1994-02-01), Faustman
Jonker, et al., Transplantation Proceedings, vol. 15, No. 1, pp. 635-638 (Mar. 1983).
Giorgi, et al., Transplantation Proceedings, vol. 15, No. 1, pp. 639-642 (Mar. 1983.
Remlinger, et al., Human Immunology, vol. 9, pp. 21-35 (1984).
Martin, et al., Transplantation Proceedings, vol. 16, No. 6, pp. 1494-1495 (Dec. 1984).
Jonker, et al., Transplantation, vol. 45, No. 4, pp. 677-682 (Apr. 1988).
Hafler, et al., J. Immunol., vol. 141, pp. 131-138 (Jul. 1, 1988).
Trinchieri, Advances in Immunology, vol. 47, pp. 272-303 (1989).
Auchincloss, et al., Fundamental Immunology, Second Edition, Paul, ed., pp. 889-922, Raven Press, Ltd., New York (1989).
Xia, et al., Rat Hybridomas and Rat Monovlonal Antibodies, Bazin, ed., pp. 309-322, CRC Press, Inc., Boca Raton, Florida (1990).
Sharabi, et al., J. Exp. Med., vol. 172, pp. 195-202 (Jul. 1990).
Bromberg, et al., Transplantation, vol. 51, pp. 219-225 (Jan. 1991).
Bollinger, et al., Transplantation Proceedings, vol. 23, No. 1, pp. 578-588 (Feb. 1991).
De La Parra, et al., Belgian Journal of Zoology, vol. 121, Supp. 1, p. 13 (Nov. 1991).
Guckel, et al., J. Exp. Med., vol. 174, pp. 957-967 (Nov. 1991).
Berlin, et al., Transplantation, vol. 53, No. 4, pp. 840-849 (Apr. 1992).
Chavin, et al., Transplantation, vol. 54, No. 2, pp. 286-291 (Aug. 1992).
Kahan, Curr. Opin. Immunol., vol. 4, pp. 553-560 (Aug. 1992).
Monaco, Immunomethods, vol. 2, pp. 159-170 (1993).
Rebellato, et al., Transplantation Proceedings, vol. 25, No. 1, pp. 598-599 (Feb. 1993).
Harris, et al., Tibtech, vol. 11, pp. 42-44 (Feb. 1993).
Emery, et al., Exp. Opin. Invest. Drugs, vol. 3, No. 3, pp. 241-251 (1994).
Paul (ED) Fundamental Immunology 3rd Ed. p. 242 only Raven Press NY 1993.
Edgington Biotechnology 10: 383-389 (1992).

Affiliated with

Also associated with

Rating

LO-CD2a antibody and uses thereof for inhibiting T cell activati does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with LO-CD2a antibody and uses thereof for inhibiting T cell activati, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and LO-CD2a antibody and uses thereof for inhibiting T cell activati will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2286707